Alpha Cognition Inc.

# Alpha Cognition Inc. (ACOG)

Based in Vancouver, British Columbia, Alpha Cognition is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company's primary commercial-stage program is ZUNVEYL, an oral tablet formulation targeting Alzheimer's disease. The company is also evaluating ZUNVEYL in combination with memantine for moderate-to-severe Alzheimer's disease treatment.

Alpha Cognition's pipeline includes several pre-clinical programs across multiple therapeutic areas. ALPHA-1062 is being developed in both sublingual and intranasal formulations for acute pancreatitis and cognitive impairment related to mild traumatic brain injury, respectively. The company also maintains early-stage programs designated ALPHA-0602, ALPHA-0702, and ALPHA-0802 targeting neurodegenerative conditions including amyotrophic lateral sclerosis and spinal muscular atrophy.

The company operates primarily across the United States and Canada. Founded in 2000, Alpha Cognition operates as a publicly listed biopharmaceutical entity on Nasdaq with a market capitalization of approximately $0.1 billion. As a development-stage company, the organization relies on capital deployment to advance its clinical and pre-clinical programs toward potential regulatory approval and commercialization.